This percentage is considered higher than clinically standard CSF markers (Aβ = 78.4% and tau = 77.6%), as shown in a comparative study of 94 AD patients, 41 non-AD patients, and 40 controls [137]. The gene discussed is MAPT; the disease is Alzheimer disease.